American Association of Orthopedic Surgeons and American College of Chest Physicians Guidelines for Venous Thromboembolism Prevention in Hip and Knee Arthroplasty Differ What Are the Implications for Clinicians and Patients?

被引:156
作者
Eikelboom, John W. [2 ,3 ,5 ]
Karthikeyan, Ganesan [2 ,3 ]
Fagel, Nick [4 ]
Hirsh, Jack [1 ,2 ,3 ]
机构
[1] Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada
[2] McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada
[3] Hamilton Hlth Sci & McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada
[4] Univ Amsterdam, NL-1012 WX Amsterdam, Netherlands
[5] McMaster Univ, Hamilton Gen Hosp, Thrombosis Serv, Hamilton, ON L8S 4L8, Canada
关键词
arthroplasty; guidelines; venous thromboembolism prevention; MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; RANDOMIZED-TRIALS; ELECTIVE HIP; UNFRACTIONATED HEPARIN; DABIGATRAN ETEXILATE; PULMONARY-EMBOLISM; MEDICAL PATIENTS;
D O I
10.1378/chest.08-2655
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The recently published American Association of Orthopedic Surgeons (AAOS) guidelines For the prevention of venous thromboembolism (VTE) in patients undergoing hip or knee surgery conflict with long-established and widely used American College of Chest Physicians (ACCP) guidelines. Both guidelines accepted that the most important goal of thromboprophylaxis in patients undergoing hip or knee replacement is to prevent pulmonary, embolism (PE). The ACCP guidelines included asymptomatic (and symptomatic) deep vein thrombosis (DVT) detected by venography as a measure of the efficacy of thromboprophylaxis, whereas the AAOS rejected DV as a valid outcome because the panelists considered the link between DVT and PE to be unproven. The AAOS position is inconsistent with evidence from imaging studies linking DVT with PE and from clinical studies demonstrating a parallel reduction of DVT and PE when antithrombotic agents are compared with placebo or untreated controls. The AAOS panel ignored the randomized data demonstrating that thromboprophylaxis reduces both DVT and PE, and many of their recommendations are based on expert opinion and lack a scientific basis. We recommend the ACCP guidelines because the methodology is explicit and rigorous and the treatment recommendations reflect all of the evidence from the randomized trials. Adoption of the ACCP guideline will ensure that patients undergoing hip and knee arthroplasty receive the best available therapies for prevention of VTE and reduce disability and death due to this common and potentially preventable condition. (CHEST 2009; 135:513-520)
引用
收藏
页码:513 / 520
页数:8
相关论文
共 36 条
[1]   Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery [J].
Agnelli, G ;
Bergqvist, D ;
Cohen, AT ;
Gallus, AS ;
Gent, M .
BRITISH JOURNAL OF SURGERY, 2005, 92 (10) :1212-1220
[2]  
*AM AC ORTH SURG C, 2007, CLIN GUID PREV SYMPT
[3]  
[Anonymous], 2008, SURG GEN CALL ACT PR
[4]   Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial [J].
Cohen, AT ;
Davidson, BL ;
Gallus, AS ;
Lassen, MR ;
Prins, MH ;
Tomkowski, W ;
Turpie, AGG ;
Egberts, JFM ;
Lensing, AWA .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7537) :325-327
[5]   REDUCTION IN FATAL PULMONARY-EMBOLISM AND VENOUS THROMBOSIS BY PERIOPERATIVE ADMINISTRATION OF SUBCUTANEOUS HEPARIN - OVERVIEW OF RESULTS OF RANDOMIZED TRIALS IN GENERAL, ORTHOPEDIC, AND UROLOGIC SURGERY [J].
COLLINS, R ;
SCRIMGEOUR, A ;
YUSUF, S ;
PETO, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (18) :1162-1173
[6]   Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty - Evaluation during hospitalization and three months after discharge [J].
Colwell, CW ;
Collis, DK ;
Paulson, R ;
McCutchen, JW ;
Bigler, GT ;
Lutz, S ;
Hardwick, ME .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1999, 81A (07) :932-940
[7]   USE OF ENOXAPARIN, A LOW-MOLECULAR-WEIGHT HEPARIN, AND UNFRACTIONATED HEPARIN FOR THE PREVENTION OF DEEP VENOUS THROMBOSIS AFTER ELECTIVE HIP-REPLACEMENT - A CLINICAL-TRIAL COMPARING EFFICACY AND SAFETY [J].
COLWELL, CW ;
SPIRO, TE ;
TROWBRIDGE, AA ;
MORRIS, BA ;
KWAAN, HC ;
BLAHA, JD ;
COMEROTA, AJ ;
SKOUTAKIS, VA .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1994, 76A (01) :3-14
[8]   Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a metaanalysis of the randomised trials [J].
Eikelboom, JW ;
Quinlan, DJ ;
Douketis, JD .
LANCET, 2001, 358 (9275) :9-15
[9]   Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:: the RE-MODEL randomized trial [J].
Eriksson, B. I. ;
Dahl, O. E. ;
Rosencher, N. ;
Kurth, A. A. ;
Van Dijk, N. ;
Frostick, S. P. ;
Kalebo, P. ;
Christiansen, A. V. ;
Hantel, S. ;
Hettiarachchi, R. ;
Schnee, J. ;
Buller, H. R. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (11) :2178-2185
[10]   Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty [J].
Eriksson, Bengt I. ;
Borris, Lars C. ;
Friedman, Richard J. ;
Haas, Sylvia ;
Huisman, Menno V. ;
Kakkar, Ajay K. ;
Bandel, Tiemo J. ;
Beckmann, Horst ;
Muehlhofer, Eva ;
Misselwitz, Frank ;
Geerts, William .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (26) :2765-2775